Pharmacoeconomics of mild cognitive impairment.
There is little written about the pharmacoeconomics of mild cognitive impairment (MCI), particularly with regard to intervention. The aim of the paper is to highlight methodological issues and to present some results that are of importance when drug interventions of MCI are discussed. There is a relationship between severity of dementia and costs, but to what extent such results can be extrapolated to MCI is not known. Even if it is logical to consider a postponement of the shift from MCI to dementia as cost effective, this statement must be proven, particularly in light of the insufficient knowledge about the effects of anti-dementia drugs on survival. From the Kungsholmen project in Sweden, there are indications that the postponement between MCI and manifest dementia may result in short-term benefits (a few years) of about SEK50,000 (5300 US dollars).
Wimo
Anders
A
Division of Geriatric Medicine, Neurotec, Karolinska Institutet, Stockholm, Sweden.
Winblad
Bengt
B
D002170:Canada; D003072:Cognition Disorders / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D015897:Comorbidity; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003704:Dementia / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D016527:Drug Costs; D005858:Germany; D006801:Humans; D017059:Models, Econometric; D009483:Neuropsychological Tests; D019057:Quality-Adjusted Life Years; D012720:Severity of Illness Index; D013548:Sweden / Q000453:epidemiology